Mylan: We will control Perrigo even with just 51% of shares
Mylan executive chairman Robert J. Coury commented, "As we have stated repeatedly, Mylan remains fully confident that Perrigo's shareholders will see the value in this compelling combination and that more than 80% of Perrigo ordinary shares will be tendered into Mylan's offer, once launched following the approval of Mylan shareholders.
"With that said, Mylan is fully committed and prepared to operate Perrigo as a controlled subsidiary of Mylan in the unlikely event that greater than 50%, but less than 80%, of Perrigo ordinary shares are tendered and we would like to clarify certain implications of such a situation.
"Specifically, it is important to note that Mylan would have the ability to pass Perrigo ordinary resolutions, which will allow us to control the composition of Perrigo's Board of Directors and management team, and to effectively control Perrigo's day-to-day operations.
"In addition, Mylan is satisfied that the cash flows of the Mylan-Perrigo combination can be appropriately and efficiently utilized in both controlled and wholly-owned subsidiary scenarios.
"Further, as discussed in Mylan's proxy materials, Mylan continues to believe that the combination can realize annual pre-tax anticipated operational synergies of at least $800 million from the combined operations by the end of year four and that Mylan can successfully manage any additional risks associated with operating Perrigo as a controlled subsidiary, if necessary.
"Mylan has previous experience operating controlled subsidiaries, specifically when we acquired approximately 71% of Matrix Laboratories Limited in 2007 and operated it as a controlled subsidiary until 2015." ■